Iron Chelation Therapy in Myelodysplastic Syndromes

Overview

Journal Adv Hematol

Publisher Wiley

Specialty Hematology

Date 2010 Jul 31

PMID 20672005

Citations 5

Authors

Emanuela Messa

Daniela Cilloni

Giuseppe Saglio

Affiliations

Soon will be listed here.

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload. Iron chelation therapy may be a therapeutic option for these patients, especially since the approval of oral iron chelators, which are easier to use and better accepted by the patients. The usefulness of iron chelation in MDS patients is still under debate, mainly because of the lack of solid prospective clinical trials that should take place in the future. This review aims to summarize what is currently known about the incidence and clinical consequences of iron overload in MDS patients and the state-of the-art of iron chelation therapy in this setting. We also give an overview of clinical guidelines for chelation in MDS published to date and some perspectives for the future.

Citing Articles

Transfusion avoidance in myelodysplastic neoplasms.

Griffiths E Curr Opin Hematol. 2023; 31(2):40-46.

PMID: 37982261 PMC: 11006404. DOI: 10.1097/MOH.0000000000000794.

A primary care approach to myelodysplastic syndromes.

Samiev D, Bhatt V, Armitage J, Maness L, Akhtari M Korean J Fam Med. 2014; 35(3):111-8.

PMID: 24921029 PMC: 4040428. DOI: 10.4082/kjfm.2014.35.3.111.

Iron chelation therapy in myelodysplastic syndromes: where do we stand?.

Mitchell M, Gore S, Zeidan A Expert Rev Hematol. 2013; 6(4):397-410.

PMID: 23991926 PMC: 4124619. DOI: 10.1586/17474086.2013.814456.

Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome.

Mast A, Field J Transfusion. 2012; 52(10):2078-80.

PMID: 23110731 PMC: 3589809. DOI: 10.1111/j.1537-2995.2012.03894.x.

Crosstalk between Erythropoiesis and Iron Metabolism.

Rivella S, Nemeth E, Miller J Adv Hematol. 2010; 2010.

PMID: 20862206 PMC: 2938435. DOI: 10.1155/2010/317095.

References

Tefferi A, Stone R . Iron chelation therapy in myelodysplastic syndrome - Cui bono?. Leukemia. 2009; 23(8):1373. DOI: 10.1038/leu.2009.39. View

Cappellini M, Pattoneri P . Oral iron chelators. Annu Rev Med. 2009; 60:25-38. DOI: 10.1146/annurev.med.60.041807.123243. View

Gattermann N . Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res. 2008; 31 Suppl 3:S10-5. DOI: 10.1016/S0145-2126(07)70461-7. View

Messa E, Carturan S, Maffe C, Pautasso M, Bracco E, Roetto A . Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010; 95(8):1308-16. PMC: 2913079. DOI: 10.3324/haematol.2009.016824. View

Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R . Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2009; 146(3):310-6. DOI: 10.1111/j.1365-2141.2009.07774.x. View

Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M . Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007; 78(6):487-94. DOI: 10.1111/j.1600-0609.2007.00842.x. View

Cabantchik Z, Breuer W, Zanninelli G, Cianciulli P . LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005; 18(2):277-87. DOI: 10.1016/j.beha.2004.10.003. View

Smeets M, Vreugdenhil G, Holdrinet R . Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol. 1996; 51(3):243-4. DOI: 10.1002/(SICI)1096-8652(199603)51:3<243::AID-AJH12>3.0.CO;2-H. View

Bullen J, Rogers H, Spalding P, Ward C . Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol. 2006; 55(Pt 3):251-258. DOI: 10.1099/jmm.0.46386-0. View

10.

Malcovati L, Della Porta M, Pascutto C, Invernizzi R, Boni M, Travaglino E . Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23(30):7594-603. DOI: 10.1200/JCO.2005.01.7038. View

11.

Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88. View

12.

Konen E, Ghoti H, Goitein O, Winder A, Kushnir T, Eshet Y . No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol. 2007; 82(11):1013-6. DOI: 10.1002/ajh.20980. View

13.

Kontoghiorghes G, Pattichi K, Hadjigavriel M, Kolnagou A . Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci. 2000; 23(3):211-23. DOI: 10.1016/s0955-3886(00)00089-8. View

14.

Rassool F, Gaymes T, Omidvar N, Brady N, Beurlet S, Pla M . Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?. Cancer Res. 2007; 67(18):8762-71. DOI: 10.1158/0008-5472.CAN-06-4807. View

15.

Alessandrino E, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato L . Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002; 87(12):1286-306. View

16.

Wells R, Leber B, Buckstein R, Lipton J, Hasegawa W, Grewal K . Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res. 2008; 32(9):1338-53. DOI: 10.1016/j.leukres.2008.02.021. View

17.

Zurlo M, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C . Survival and causes of death in thalassaemia major. Lancet. 1989; 2(8653):27-30. DOI: 10.1016/s0140-6736(89)90264-x. View

18.

Kruszewski M . The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol. 2004; 51(2):471-80. View

19.

Mittelman M, Lugassy G, Merkel D, Tamary H, Sarid N, Rachmilewitz E . Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines. Isr Med Assoc J. 2008; 10(5):374-6. View

20.

Chacko J, Pennell D, Tanner M, Hamblin T, Wonke B, Levy T . Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007; 138(5):587-93. DOI: 10.1111/j.1365-2141.2007.06695.x. View